References

Myasthenia Gravis in Clinical Practice

10.1590/0004-282x-anp-2022-s105 · 2022 · External reference

Myasthenic Crisis

10.1002/mus.27832 · 2023 · External reference

Generalized Myasthenia Gravis With Acetylcholine Receptor Antibodies: A Guidance for Treatment

10.1111/ene.16229 · 2024 · External reference

Current Drug Treatment of Myasthenia Gravis

10.1097/wco.0000000000001196 · 2023 · External reference

Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis: Results From the Randomized Phase 2 Vivacity‐MG Study

10.1212/wnl.0000000000207937 · 2024 · External reference

Double Filtration Plasmapheresis: Review of Current Clinical Applications

10.1111/1744-9987.13548 · 2021 · External reference

Double Filtration Plasmapheresis—10‐Year Pediatric Experience as an Alternative to Plasma Exchange

10.1016/j.transci.2020.102928 · 2020 · External reference

Efgartigimod for Generalized Myasthenia Gravis: A Multicenter Real‐World Cohort Study in China

10.1002/acn3.52142 · 2024 · External reference

Efficacy and Safety of Double‐Filtration Plasmapheresis Treatment of Myasthenia Gravis: A Systematic Review and Meta‐Analysis

10.1097/md.0000000000025622 · 2021 · External reference

Effectiveness of Double‐Filtration Plasmapheresis in Reducing Immunoglobulin and Culprit Antibody Levels in Neuroimmune Disorders: A Single‐Center Retrospective Analysis From China

10.1016/j.jneuroim.2024.578463 · 2024 · External reference

Myasthenia Gravis: Subgroup Classification and Therapeutic Strategies

10.1016/s1474-4422(15)00145-3 · 2015 · External reference

Myasthenia Gravis, Respiratory Function, and Respiratory Tract Disease

10.1007/s00415-023-11733-y · 2023 · External reference

Intensive Care due to Myasthenia Gravis: Risk Factors and Prognosis

10.1111/ene.16522 · 2024 · External reference

Myasthenia Gravis Treatment: From Old Drugs to Innovative Therapies With a Glimpse Into the Future

10.1007/s40263-023-01059-8 · 2024 · External reference

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence‐Based Approach From the Writing Committee of the American Society for Apheresis: The Ninth Special Issue

10.1002/jca.22043 · 2023 · External reference

Efgartigimod: First Approval

10.1007/s40265-022-01678-3 · 2022 · External reference

Safety, Efficacy, and Tolerability of Efgartigimod in Patients With Generalised Myasthenia Gravis (ADAPT): A Multicentre, Randomised, Placebo‐Controlled, Phase 3 Trial

10.1016/s1474-4422(21)00159-9 · 2021 · External reference

Efgartigimod Versus Intravenous Immunoglobulin in the Treatment of Patients With Impending Myasthenic Crisis

10.1038/s41598-024-79918-7 · 2024 · External reference

Safety, Tolerability, and Efficacy of Subcutaneous Efgartigimod in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (ADHERE): A Multicentre, Randomised‐Withdrawal, Double‐Blind, Placebo‐Controlled, Phase 2 Trial

10.1016/s1474-4422(24)00309-0 · 2024 · External reference

Efficacy and Safety of the Neonatal Fc Receptor Inhibitor Efgartigimod in Adults With Primary Immune Thrombocytopenia (ADVANCE IV): A Multicentre, Randomised, Placebo‐Controlled, Phase 3 Trial

10.1016/s0140-6736(23)01460-5 · 2023 · External reference

The Impact of Efgartigimod on Utilization of Therapeutic Plasma Exchange Procedures for Myasthenia Gravis in One Tertiary Medical Center

10.1002/jca.70010 · 2025 · External reference

Retrospective Review of Patients With Myasthenia Gravis Switched From Plasma Exchange Therapy to Efgartigimod Treatment

10.1002/mus.28042 · 2024 · External reference

Subcutaneous Efgartigimod PH20 in Generalized Myasthenia Gravis: A Phase 3 Randomized Noninferiority Study (ADAPT‐SC) and Interim Analyses of a Long‐Term Open‐Label Extension Study (ADAPT‐SC+)

10.1016/j.neurot.2024.e00378 · 2024 · External reference

Therapeutic Plasma Exchange Versus FcRn Inhibition in Autoimmune Disease

10.1016/j.tmrv.2023.150767 · 2024 · External reference